First big depression advance since Prozac nears FDA approval
February 14, 2019

From Bloomberg:

The U.S. Food and Drug Administration is on the brink of approving a breakthrough drug that could upend the way severe depression is treated.

Johnson & Johnson's esketamine, a close chemical cousin of the anesthetic ketamine, cleared a major hurdle on Tuesday when a panel of outside experts recommended that the FDA approve the treatment. The fast-acting antidepressant, administered via a nasal spray, is being tested in major depressive disorder and suicidal thinking. If approved, it would be the first major therapeutic advance for depression since the introduction of Prozac in 1987.

Prozac and other currently available antidepressants take weeks to work and don't help all patients, so esketamine could mark a significant shift in depression therapy.

Continue reading at Bloomberg...

You may also like

Financial concerns are affecting the health of wealthy Americans, too

"Even relatively wealthy Americans are so worried about their finances that it’s affecting their mental and physical health."

More men opting for the 'Daddy-Do-Over'

"Just as women can turn to a suite of procedures, known as the 'Mommy Makeover,' more men are embracing their own set of treatments, the 'Daddy-Do-Over'..."

Study: People ingest at least 50,000 plastic particles a year

"Health effects of ingestion of microplastics via food, water and breathing still unknown."